Weiss Ratings Reiterates "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Vanda Pharmaceuticals (NASDAQ:VNDA), indicating a negative outlook for the company's stock.
• Despite this, HC Wainwright maintains a "Buy" rating with a $20.00 price target, while other analysts have expressed varied views, resulting in a consensus rating of "Moderate Buy" with a price target of $16.50.
• In its latest earnings report, Vanda Pharmaceuticals posted a loss of ($0.46) EPS, which was below the consensus estimate, and reported revenues of $52.59 million, missing expectations of $54.77 million.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

VNDA has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.

Vanda Pharmaceuticals Trading Up 0.2%

VNDA stock traded up $0.01 during mid-day trading on Friday, hitting $5.50. 514,904 shares of the company were exchanged, compared to its average volume of 573,210. The business has a fifty day simple moving average of $4.90 and a 200-day simple moving average of $4.61. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $5.62.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The company had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. Bailard Inc. raised its holdings in Vanda Pharmaceuticals by 16.2% during the second quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 3,631 shares in the last quarter. Jane Street Group LLC raised its holdings in Vanda Pharmaceuticals by 6.1% during the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company's stock worth $373,000 after purchasing an additional 4,533 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Vanda Pharmaceuticals by 18.9% during the first quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company's stock worth $151,000 after purchasing an additional 5,210 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in Vanda Pharmaceuticals by 17.8% during the second quarter. Los Angeles Capital Management LLC now owns 44,696 shares of the biopharmaceutical company's stock worth $211,000 after purchasing an additional 6,765 shares in the last quarter. Finally, CWM LLC raised its holdings in Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 7,575 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.